Health Care & Life Sciences » Biotechnology | Cyclacel Pharmaceuticals Inc.

Cyclacel Pharmaceuticals Inc. | Ownership

Companies that own Cyclacel Pharmaceuticals Inc.

Name
Shares Held
% Shares Out
Change In Shares
% of Assets
As of Date
Eastern Capital Ltd.
2,167,261
18.07%
850,000
1.08%
08/10/2017
The Vanguard Group, Inc.
372,497
3.11%
200
0%
06/30/2018
Renaissance Technologies LLC
91,400
0.76%
76,500
0%
06/30/2018
Raymond James Financial Services Advisors, Inc.
40,125
0.33%
10,000
0%
06/30/2018
PanAgora Asset Management, Inc.
29,531
0.25%
0
0%
06/30/2018
Virtu Financial BD LLC
29,033
0.24%
-10,580
0%
06/30/2018
Sabby Capital LLC
25,000
0.21%
25,000
0.02%
06/30/2018
Geode Capital Management LLC
21,692
0.18%
0
0%
06/30/2018
Citadel Advisors LLC
13,454
0.11%
13,454
0%
06/30/2018
Northern Trust Investments, Inc.
13,399
0.11%
0
0%
06/30/2018

About Cyclacel Pharmaceuticals

View Profile
Address
200 Connell Drive
Berkeley Heights New Jersey 07922
United States
Employees -
Website http://www.cyclacel.com
Updated 07/08/2019
Cyclacel Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It uses cell cycle, transcriptional regulation and DNA damage response biology to develop innovative, targeted medicines for cancer and other proliferative diseases. The company builds a diversified biopharmaceutical business, which is focused in hematology and oncology based on a pipeline of novel drug candidates.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.